Works of our laboratory demonstrated that intermediate filaments, which are one of the three cytoskeleton elements, can bind tubulin dimers in specific sites named TBS (Tubulin-Binding Site). Some of these peptides corresponding to TBS sequences can inhibit in vitro tubulin polymerization in microtubules (MT). Works in this thesis consist of continuing the structural and functional characterization of these peptides. Thus, it has been possible to show that one of these peptides from vimentin protein, Vim-TBS.58-81, is able to enter in T98G human glioblastoma cells and to localize in the nucleus of the cells. When coupled to a pro-apoptotic peptide acting in the nuclear compartment, it is able to inhibit cell proliferation. Another peptide f...
Glioblastoma stem cells correspond to brain tumor-initiating cells (BTICs) that have been identified...
Glioblastoma are the most frequent and aggressive tumour of the nervous system despite surgical rese...
The present invention provides a new drug to treat malignant glioma, which is the most prevalent typ...
Works of our laboratory demonstrated that intermediate filaments, which are one of the three cytoske...
In the laboratory, investigations on neurofilament biology and on their interactions with other cyto...
The Iaboratory discovered the presence of tubulin binding sites (TBS) on intermediate filaments, lik...
Des travaux menés au laboratoire sur la biologie des neurofilaments et sur leurs interactions avec l...
We previously reported that a 24 amino acid peptide (NFL-TBS.40-63) corresponding to the tubulin-bin...
Despite aggressive treatment regimes, glioma remains a largely fatal disease. Current treatment limi...
Les travaux menés au laboratoire ont mis en évidence des sites de liaison de la tubuline (TBS pour T...
Cell-penetrating peptides (CPPs) can translocate through the plasma membrane and localize in differe...
We previously reported that a 24 amino acid peptide (NFL-TBS.40-63) corresponding to the tubulin-bin...
We previously reported that a 24 amino acid peptide (NFL-TBS.40-63) corresponding to the tubulin-bin...
We previously described a neurofilament derived cell-penetrating peptide, NFL-TBS.40-63, that specif...
NFL-TBS.40–63 is a 24 amino acid peptide corresponding to the tubulin-binding site located on the li...
Glioblastoma stem cells correspond to brain tumor-initiating cells (BTICs) that have been identified...
Glioblastoma are the most frequent and aggressive tumour of the nervous system despite surgical rese...
The present invention provides a new drug to treat malignant glioma, which is the most prevalent typ...
Works of our laboratory demonstrated that intermediate filaments, which are one of the three cytoske...
In the laboratory, investigations on neurofilament biology and on their interactions with other cyto...
The Iaboratory discovered the presence of tubulin binding sites (TBS) on intermediate filaments, lik...
Des travaux menés au laboratoire sur la biologie des neurofilaments et sur leurs interactions avec l...
We previously reported that a 24 amino acid peptide (NFL-TBS.40-63) corresponding to the tubulin-bin...
Despite aggressive treatment regimes, glioma remains a largely fatal disease. Current treatment limi...
Les travaux menés au laboratoire ont mis en évidence des sites de liaison de la tubuline (TBS pour T...
Cell-penetrating peptides (CPPs) can translocate through the plasma membrane and localize in differe...
We previously reported that a 24 amino acid peptide (NFL-TBS.40-63) corresponding to the tubulin-bin...
We previously reported that a 24 amino acid peptide (NFL-TBS.40-63) corresponding to the tubulin-bin...
We previously described a neurofilament derived cell-penetrating peptide, NFL-TBS.40-63, that specif...
NFL-TBS.40–63 is a 24 amino acid peptide corresponding to the tubulin-binding site located on the li...
Glioblastoma stem cells correspond to brain tumor-initiating cells (BTICs) that have been identified...
Glioblastoma are the most frequent and aggressive tumour of the nervous system despite surgical rese...
The present invention provides a new drug to treat malignant glioma, which is the most prevalent typ...